Compare LOOP & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | LPCN |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7M | 61.8M |
| IPO Year | 2010 | 2011 |
| Metric | LOOP | LPCN |
|---|---|---|
| Price | $1.49 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 120.3K | ★ 390.7K |
| Earning Date | 01-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.27 | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,889,000.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | $74.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.88 | $1.81 |
| 52 Week High | $2.29 | $12.37 |
| Indicator | LOOP | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 25.32 |
| Support Level | $1.44 | N/A |
| Resistance Level | $1.75 | $3.40 |
| Average True Range (ATR) | 0.10 | 0.56 |
| MACD | 0.01 | -0.47 |
| Stochastic Oscillator | 73.06 | 2.54 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.